Abstract: To improve pressure measurement reliability and safety of a battery cell and finely control pressure, the disclosure of the present application provides a battery cell pressing device comprising: a battery cell; a plurality of upper plates disposed above the battery cell; a plurality of lower plates disposed below the battery cell; a first pressing member interposed between the plurality of upper plates; and a second pressing member interposed between the plurality of lower plates, wherein a magnetic force is generated at the first pressing member and the second pressing member by an applied current.

Abstract: A solid oxide cell stack includes first and second interconnects, a solid oxide cell disposed between the first and second interconnects, and a porous metal foam between the first interconnect and the solid oxide cell, wherein the porous metal foam includes a carbon nanostructure formed on a surface thereof.

Abstract: An embodiment electrolyte solution includes a lithium salt, a solvent, and a functional additive, wherein the functional additive includes 4-((tert-butoxydimethylsilyl)methyl)-5-methyl-1,3-dioxol-2-one represented by as an electrode film additive. An embodiment lithium secondary battery includes the above-described electrolyte solution, a positive electrode including a positive electrode active material including Ni, Co, and Mn, a negative electrode including a carbon-based negative electrode active material or a silicon-based negative electrode active material, and a separator interposed between the positive electrode and the negative electrode.

Abstract: An embodiment electrolyte solution includes a lithium salt, a solvent, and a functional additive, wherein the functional additive includes an electrode film additive of 2-(dodec-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane represented by An embodiment lithium secondary battery includes this electrolyte solution, a positive electrode including a positive-electrode active material including Ni, Co, and Mn, a negative electrode including a negative-electrode active material including a carbon (C)-based material or a silicon (Si)-based material, and a separator interposed between the positive electrode and the negative electrode.

Abstract: Disclosed herein is a method for integrated anomaly detection. The method includes detecting a thing object and a human object in input video using a first neural network, and tracking the human object, and detecting an anomalous situation based on an object detection result and a human object tracking result.

Abstract: A pouch-type battery case includes a cup portion, which accommodates therein an electrode assembly formed by stacking an electrode and a separator, and a plurality of die edges connecting an outer wall of the cup portion to a side extending from the outer wall. The die edges include a first region, which is rounded at a first radius (r1) of curvature and at which an electrode tab extending from the electrode is positioned, and a second region which is other than the first region and rounded at one or more second radii (r2, r3, r4) of curvature less than or equal to the first radius (r1) of curvature. The second region is divided into an inner region and an outer region with respect to the first region, and the radius (r2) of curvature in the inner region differs from the radii (r3, r4) of curvature in the outer region.

Abstract: Provided are a composition for inducing direct conversion from a somatic cell into a motor neuron, a motor neuron induced through direct conversion by introducing the composition into a somatic cell, a pharmaceutical composition for the prevention or treatment of nervous system disease and injury, a cell therapeutic agent, a composition for screening for a drug for the prevention or treatment of nervous system disease and injury, and a 3D printing biomaterial composition for constructing artificial tissue. When a composition of one aspect is used, differentiation from a somatic cell into a motor neuron can be efficiently induced through the expression of direct conversion inducers without going through the pluripotency stage of dedifferentiated stem cells. Thus, nervous system disease and injury can be effectively prevented and treated using the composition.

Abstract: The present invention relates to a composition for inducing direct conversion from a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell (iHSC), a hepatocyte, and a cholangiocyte, and a method of direct conversion of a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell, a hepatocyte, and a cholangiocyte.

Abstract: Provided are a composition and method for inducing direct conversion from a somatic cell into a myeloid cell and use thereof, in which differentiation from a somatic cell into a myeloid cell can be efficiently induced through the expression of a single direct conversion inducer without undergoing the pluripotency stage of induced pluripotent stem cells, and thus, the composition can be widely used as an effective preventive and therapeutic agent for immune diseases.

Abstract: The present invention relates to a composition for inducing direct transdifferentiation into oligodendrocyte progenitor cells (OPCs) from somatic cells, the composition containing at least one protein selected from the group consisting of direct transdifferentiation factors OCT4, SOX1, SOX2, SOX10, OLIG2, NKX2.2, and NKX6.

Abstract: Provided are a hydrogel patch, a method of preparing the same, and a composition for the treatment of spinal cord injury including the hydrogel patch. The hydrogel patch enables a spinal cord injury patient to be treated in a manner which is non-invasive to the spinal cord.

Abstract: The present invention relates to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell and a use thereof and, more specifically, to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell, a pharmaceutical composition for the prevention or treatment of ischemic vascular diseases, a cell therapeutic agent for the prevention or treatment of ischemic vascular diseases, a composition for screening a therapeutic drug for ischemic vascular diseases, a 3D printing biological material composition for the production of an artificial tissue for the treatment of ischemic vascular diseases, and a method for direct transdifferentiation of a somatic cell into a vascular progenitor cell.

Abstract: The present invention relates to a composition for inducing direct conversion from a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell (iHSC), a hepatocyte, and a cholangiocyte, and a method of direct conversion of a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell, a hepatocyte, and a cholangiocyte.

Abstract: The present invention relates to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell and a use thereof and, more specifically, to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell, a pharmaceutical composition for the prevention or treatment of ischemic vascular diseases, a cell therapeutic agent for the prevention or treatment of ischemic vascular diseases, a composition for screening a therapeutic drug for ischemic vascular diseases, a 3D printing biological material composition for the production of an artificial tissue for the treatment of ischemic vascular diseases, and a method for direct transdifferentiation of a somatic cell into a vascular progenitor cell.

Abstract: The present invention relates to a method of generating an induced pluripotent stem (iPS) cell comprising the step of introducing into a target cell one or two coding sequences each giving rise upon transcription to a factor that contributes to the reprogramming of said target cell into an induced pluripotent stem cell and selected from Oct3/4 or a factor belonging to the Myc, Klf and Sox families of factors, wherein the target cell endogenously expresses at least the factors that are not encoded by the coding sequences to be introduced and selected from Oct3/4 or factors belonging to the Myc, Klf and Sox families of factors, and wherein the cell resulting from the introduction of the one or two coding sequences expresses the combination of factor Oct3/4 and at least one factor of each family of factors selected from the group of Myc, Klf and Sox.

Abstract: The present invention relates to a composition for inducing direct transdifferentiation into oligodendrocyte progenitor cells (OPCs) from somatic cells, the composition containing at least one protein selected from the group consisting of direct transdifferentiation factors OCT4, SOX1, SOX2, SOX10, OLIG2, NKX2.2, and NKX6.

Abstract: The present invention relates to a method of generating an induced pluripotent stem (iPS) cell comprising the step of introducing into a target cell one or two coding sequences each giving rise upon transcription to a factor that contributes to the reprogramming of said target cell into an induced pluripotent stem cell and selected from Oct3/4 or a factor belonging to the Myc, Klf and Sox families of factors, wherein the target cell endogenously expresses at least the factors that are not encoded by the coding sequences to be introduced and selected from Oct3/4 or factors belonging to the Myc, Klf and Sox families of factors, and wherein the cell resulting from the introduction of the one or two coding sequences expresses the combination of factor Oct3/4 and at least one factor of each family of factors selected from the group of Myc, Klf and Sox.

Abstract: The present invention relates to a method of generating an induced pluripotent stem (iPS) cell comprising the step of introducing into a target cell one or two coding sequences each giving rise upon transcription to a factor that contributes to the reprogramming of said target cell into an induced pluripotent stem cell and selected from Oct3/4 or a factor belonging to the Myc, Klf and Sox families of factors, wherein the target cell endogenously expresses at least the factors that are not encoded by the coding sequences to be introduced and selected from Oct3/4 or factors belonging to the Myc, Klf and Sox families of factors, and wherein the cell resulting from the introduction of the one or two coding sequences expresses the combination of factor Oct3/4 and at least one factor of each family of factors selected from the group of Myc, Klf and Sox.

Abstract: A filter device for a water purifier including a filter unit having a flange having an inlet, an outlet, an optional discharge port, opposite engaging protrusions, and opposite engaging recesses; a connecting member fitted into the flange so as to be connected with the inlet, the outlet, and optional discharge port and having inner communicating passages so as to be connected with respective connecting holes, a cap member fitted around the flange to cover the connecting member and having on an outer circumference connecting ports communicating with the respective connecting holes, the cap member having opposite engaging holes corresponding to the engaging protrusions and opposite engaging grooves corresponding to the engaging recesses, and a fixing member engaging on an inner end with the engaging recess through the engaging groove.